Radiopharmaceuticals

Radiopharmaceuticals are radioactive drugs used for diagnostic imaging and therapeutic interventions in nuclear medicine. By targeting specific organs or tissues, radiopharmaceuticals provide valuable insights into physiological processes and deliver targeted radiation therapy for various diseases.

Overview

Radiopharmaceuticals are radioactive compounds administered to patients for medical purposes. In diagnostic imaging, they accumulate in specific organs and emit gamma rays or positrons detected by specialised cameras (SPECT or PET), allowing visualisation of organ function. In therapy, they deliver targeted radiation to diseased tissues, such as tumours. Radiopharmaceuticals provide functional information for early disease detection and enable targeted therapy that minimises damage to healthy surrounding tissues.

Techniques

Diagnostic Radiopharmaceuticals: Used for imaging organ function and detecting abnormalities.
Therapeutic Radiopharmaceuticals: Used for targeted radiation therapy of diseased tissues.
Positron Emission Tomography (PET) Radiopharmaceuticals: Emit positrons for PET imaging.
Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals: Emit gamma rays for SPECT imaging.

Use cases

Cancer Diagnosis and Treatment: Use of PET and SPECT radiopharmaceuticals for tumour imaging and targeted radionuclide therapy.
Cardiovascular Imaging: Assessment of blood flow and heart function using SPECT radiopharmaceuticals.
Neurological Imaging: Diagnosis of neurological disorders using PET and SPECT radiopharmaceuticals.
Thyroid Disease Treatment: Use of radioactive iodine radiopharmaceuticals for thyroid cancer and hyperthyroidism.

Radiological risks

Radiological risks involve the exposure of medical personnel and patients to ionising radiation. For source-based production in reactors and the handling of radiopharmaceuticals, challenges include managing the radioactive inventory and medical waste. For electricity-generated production in cyclotrons, hazards are limited to prompt radiation during production. Strict safety protocols, shielding, and monitoring are used to ensure safety.

Deployment risks

Deployment is highly dependent on the isotope supply chain. Source-based isotopes from reactors involve time-critical logistics and the significant costs of management of sources. Electricity-generated isotopes produced in cyclotrons require high capital investment and a stable power supply. Both require specialised technical expertise and rigorous regulatory compliance for radioactive material disposal.

Proliferation risks

There are no proliferation risks as there is no nuclear material involved in this application.

Join the Nuclear for Good Community

We are a global network of organisations and individuals advancing the safe, secure, and equitable use of peaceful nuclear technologies to achieve environmental sustainability, energy security, and global development goals.

By joining the Nuclear for Good Community, you become part of this collective effort to harness nuclear innovation for people and the planet.

Prefix

First Name

Last Name

Email Address *

Country *

Occupation *

Organisation *

Please tell us, in a few sentences, what nuclear technology means to you — professionally, personally, or both.

We envision a future where nuclear technologies’ benefits are felt by everyone in their day-to-day lives